Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 63.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 3,749,486 shares of the company's stock after acquiring an additional 1,451,770 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 2.61% of Denali Therapeutics worth $109,223,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Denali Therapeutics by 12.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,719 shares of the company's stock valued at $866,000 after buying an additional 3,316 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Denali Therapeutics by 230.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,625 shares of the company's stock worth $805,000 after purchasing an additional 19,259 shares in the last quarter. FMR LLC raised its stake in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Denali Therapeutics by 20.0% during the third quarter. The Manufacturers Life Insurance Company now owns 206,819 shares of the company's stock valued at $6,025,000 after buying an additional 34,538 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Denali Therapeutics by 14.5% during the 3rd quarter. Fisher Asset Management LLC now owns 547,331 shares of the company's stock valued at $15,944,000 after acquiring an additional 69,223 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares of the company's stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the transaction, the director now owns 29,096 shares of the company's stock, valued at approximately $844,656.88. This represents a 50.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,578 shares of company stock worth $2,474,440. 7.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on DNLI. Cantor Fitzgerald lowered shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. HC Wainwright restated a "buy" rating and set a $90.00 price objective on shares of Denali Therapeutics in a research report on Thursday, November 7th. JPMorgan Chase & Co. decreased their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Jefferies Financial Group increased their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $38.90.

Denali Therapeutics Stock Up 2.5 %

DNLI traded up $0.63 during trading hours on Monday, reaching $25.63. 593,286 shares of the company's stock traded hands, compared to its average volume of 1,066,979. The firm has a market capitalization of $3.69 billion, a PE ratio of -9.06 and a beta of 1.40. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33. The firm has a 50-day moving average price of $27.29 and a 200 day moving average price of $24.53.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the previous year, the company posted ($0.72) earnings per share. Equities analysts predict that Denali Therapeutics Inc. will post -2.69 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.